Currently licensed influenza vaccines often aim at the induction of virus-neutralizing antibodies that can protect against morbidity induced by infection with a virus if it antigenically matches the vaccine. Immune factors other than neutralizing antibodies also contribute to protection without the need of full virus neutralization. This type of infection-permissive immunity often correlates with protection against a broader range of influenza viruses and understanding the underlying mechanisms is important for pandemic preparedness. My research focuses on infection-permissive immunity using the murine influenza challenge model. Innate and adaptive immune responses upon infection are monitored in vaccinated or virus-exposed mice. We aim at understanding how antiviral immune responses that are induced or boosted by virus infection correlate with the broader protection of the infection-permissive host.
Schotsaert M, García-Sastre A. Inactivated influenza virus vaccines: the future of TIV and QIV. Curr Opin Virol. 2017 Apr;23:102-106. doi: 10.1016/j.coviro.2017.04.005. Epub 2017 May 12. Review.
Schotsaert M, Ysenbaert T, Smet A, Schepens B, Vanderschaeghe D, Stegalkina S, Vogel TU, Callewaert N, Fiers W, Saelens X. Long-Lasting Cross-Protection Against Influenza A by Neuraminidase and M2e-based immunization strategies. Sci Rep. 2016 Apr 13;6:24402. doi: 10.1038/srep24402.
Schotsaert M, García-Sastre A. A High-Resolution Look at Influenza Virus Antigenic Drift. J Infect Dis. 2016 Oct 1;214(7):982. doi: 10.1093/infdis/jiw183. Epub 2016 May 6. No abstract available.
Schotsaert M, García-Sastre A. Influenza vaccines: a moving interdisciplinary field. Viruses. 2014 Oct 9;6(10):3809-26. doi: 10.3390/v6103809. Review.
Schotsaert M, Ysenbaert T, Neyt K, Ibañez LI, Bogaert P, Schepens B, Lambrecht BN, Fiers W, Saelens X. Natural and long-lasting cellular immune responses against influenza in the M2e-immune host. Mucosal Immunol. 2013 Mar;6(2):276-87. doi: 10.1038/mi.2012.69. Epub 2012 Jul 18.